Alternative technologies in cervical cancer screening: A randomised evaluation trial

BMC Public Health

Volumn 6, Issue , 2006, Pages

  Anttila, Ahti ^a   Hakama, Matti ^a,b   Kotaniemi Talonen, Laura ^a   Nieminen, Pekka ^c  

^a FINNISH CANCER REGISTRY   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL TECHNOLOGY; UTERINE CERVIX CANCER; WART VIRUS; FINLAND; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PRECANCER; PROCEDURES; PROGRAM EVALUATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADULT; CYTOLOGICAL TECHNIQUES; DNA, VIRAL; FEMALE; FINLAND; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PROGRAM EVALUATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 33750522430     PISSN: 14712458     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-6-252     Document Type: Article

References (48)

1. Hakama M: Trends in the incidence of cervical cancer in the Nordic countries. In Trends in Cancer Incidence Edited by: K. M. Washington: Hemisphere Publishing Corporation; 1982:279-292.
2. Laara E, Day NE, Hakama M: Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987, 1(8544):1247-9.
3. Sasieni P, Cuzick J, Farmery E: Accelerated decline in cervical cancer mortality in England and Wales. Lancet 1995, 346(8989):1566-7.
4. Sankila R, Demaret E, Hakama M, Lynge E, Schouten LJ, Parkin DM, editors: Evaluation and monitoring od screening programmes. Brussels: European Comission, Europe Against Cancer Programme; 2001.
5. Peto J, Gilham C, Fletcher O, Matthews FE: The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004, 364(9430):249-56.
6. The Working group of IARC: IARC Handbooks of Cancer Prevention. In Cervical Cancer Volume 10. Lyon: IARCPress; 2005.
7. Finnish Cancer Registry: Cancer in Finland 2002 and 2003. Cancer statistics of the National Research and Development Centre for Welfare and Health (STAKES). Helsinki: Cancer Society of Finland; 2005.
8. Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M, Weiderpass E: Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004, 91(5):935-41.
9. Hristova L, Hakama M: Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol 1997, 36(Suppl 9):1-60.
10. Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. In IARC CancerBase No. 5. Version 2.0 Lyon: IARCPress; 2004.
11. Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, Hakama M, Parkin DM: Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005, 14(3):677-86.
12. Kok MR, Boon ME: Consequences of neural network technology for cervical screening: increase in diagnostic consistency and positive scores. Cancer 1996, 78(1):112-7.
13. Wilbur DC, Bonfiglio TA, Rutkowski MA, Atkison KM, Richart RM, Lee JS, Patten SF Jr: Sensitivity of the AutoPap 300 QC System for cervical cytologic abnormalities. Biopsy data confirmation. Acta Cytol 1996, 40(1):127-32.
14. Nieminen P, Kotaniemi L, Hakama M, Tarkkanen J, Martikainen J, Toivonen T, Ikkala J, Luostarinen T, Anttila A: A randomised public-health trial on automation-assisted screening for cervical cancer in Finland: Performance with 470,000 invitations. Int J Cancer 2005, 115(2):307-311.
15. Noorani HZ, Brown A, Skidmore B, Stuart GCE: Liquid-based cytology and human papillomavirus testing in cervical cancer screening. Technology report. Ottawa: Canadian Coordinating Office for Health Technology Assessment 2003. Report No.: no 40.
16. Arbyn MMA: Is Liquid Based Cytology an Effective Alternative for the Conventional Pap Smear to Detect Cervical Cancer Precursors? In A Systematic Review and Meta-analysis. IPH/EPI-reports 10 Brussels: Scientific Institute of Public Health; 2003.
17. Rozendaal L, Walboomers JM, van der Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJ, van Ballegooijen M, Meijer CJ: PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996, 68(6):766-9.
18. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, van Ballegooijen M, van den Akker E: A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999, 3(14 i-iv):1-196.
19. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P: Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003, 362(9399):1871-6.
20. Nieminen P, Vuorma S, Viikki M, Hakama M, Anttila A: Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. Bjog 2004, 111(8):842-8.
21. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M: Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005, 93(8):862-7.
22. Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, Onsrud M, Thoresen S: DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 2005, 97(3):908-15.
23. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B: Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005, 14(2):367-72.
24. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(5):342-50.
25. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347(21):1645-51.
26. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(9447):1757-65.
27. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(5):271-8.
28. Koss LG: The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. Jama 1989, 261(5):737-43.
29. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000, 132(10):810-9.
30. van Oortmarssen GJ, Habbema JD: Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991, 64(3):559-65.
31. Hakama M, Miller AB, Day NE: Screening for cancer of the uterine cervix. IARC scientific publications No. 76. Lyon: International Agency for Research on Cancer; 1986.
32. Nieminen P, Kotaniemi-Talonen L, Hakama M, Tarkkanen J, Martikainen J, Toivonen T, Ikkala J, Anttila A: Randomised evaluation trial on automation-assisted screening for cervical cancer: Results after 777 000 invitations. in press.
33. Council Recommendation of 2nd December on Cancer Screening: The Council of the European Union. 2003.
34. Tyczynski JE, Demaret E, Parkin DM, editors: Standards and Guidelines for Cancer Registration in Europe. In IARC Technical Publication No. 40 Lyon: IARC press; 2003.
35. Anttila A, Ronco G, Lynge E, Fender M, Arbyn M, Baldauf J-J, Patnick J, McCoogan E, Hakama M, Miller AB: Epidemiological guidelines for quality assurance in cervical cancer screening. In European guidelines for quality assurance on cervical cancer screening 2nd edition. Edited by: Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H. Brussels: European Community in press.
36. Nieminen P, Hakama M, Viikki M, Tarkkanen J, Anttila A: Prospective and randomised public-health trial on neural networkassisted screening for cervical cancer in Finland: results of the first year. Int J Cancer 2003, 103(3):422-6.
37. Viikki M, Pukkala E, Hakama M: Risk of cervical cancer after a negative Pap smear. J Med Screen 1999, 6(2):103-7.
38. Anttila A, Laara E: Cervix cancer: Geographical correlations. Evaluation and Monitoring of Screening Programmes. Brussels: European Comission, Europe Against Cancer Programme 2000:77-97.
39. Gustafsson L, Ponten J, Bergstrom R, Adami HO: International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 1997, 71(2):159-65.
40. StataCorp: Stata Statistical Software: Release 8. College Station, TX: StataCorp LP 2005.
41. Blackwelder WC: Equivalence trials. In Encyclopedia of biostatistics Edited by: Armitage P, Colton T. Chichester: John Wiley & Sons; 1999:1367-1372.
42. Hakama M: Screening. In Oxford Textbook of Public Health: Applications in Public Health Edited by: Holland WW, Detels R, Knox G. Oxford, New York, Toronto: Oxford University Press; 1991:91-106.
43. Hakama M, Pukkala E, Heikkila M, Kallio M: Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. Bmj 1997, 314(7084):864-7.
44. Malila N, Anttila A, Hakama M: Colorectal cancer screening in Finland: details of the national screening programme implemented in Autumn 2004. J Med Screen 2005, 12(1):28-32.
45. Arbyn M, Dillner J, Schenck U, Nieminen P, Weiderpass E, Baldauf JJ, Da Silva D, Jordan J, Ronco G, McCoogan E, Patnick J, Sparen P, Real O: Methods for screening and diagnosis. In European guidelines for quality assurance on cervical cancer screening 2nd edition. Edited by: Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H. Brussels: European Community in press.
46. Davies P, Arbyn M, Dillner J, Kitchener HC, Meijer CJ, Ronco G, Hakama M: A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 2005.
47. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R: Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998, 91(4):626-631.
48. van Ballegooijen M, van den Akker-van Marle E, Patnick J, Lynge E, Arbyn M, Anttila A, Ronco G, Dik J, Habbema F: Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000, 36(17):2177-88.